Daniel Rutrick
Watertown, MANPI 1568499242
Payments from drug & device makers
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$13,688,442in research payments, 2019–2025
Across 518 payments — averaging $26,426 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$5.4M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3.4M
- Boehringer Ingelheim International GmbH$2.1M
- AbbVie$1.4M
- Acadia Pharmaceuticals Inc$771K
- Sage Therapeutics, LLC$413K
- plus $258K from 4 others
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $793 |
| Alprazolam | 47 | $418 |
| Clonazepam | 30 | $337 |
| Diazepam | 12 | $250 |
| Escitalopram Oxalate | 11 | $85 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.